Table 1 Univariate analysis of adverse outcomes in preeclampsia (chi-square test)

Age

0.014

0.907

  < 35

452(83.70%)

150(83.30%)

  ≥ 35

88(16.30%)

30(16.70%)

Gestational age

134.815

 < 0.001***

  < 34

28(5.20%)

59(32.70%)

 34–37

113(20.90%)

64(35.60%)

 ≥ 37

399(73.90%)

57(31.70%)

 Primipara

333(61.70%)

103(57.20%)

1.116

0.291

Type of operation

7.475

0.006**

 Natural labor

74(13.70%)

11(6.10%)

 Cesarean section

466(86.30%)

169(93.90%)

IVF-ET

23(4.30%)

6(3.30%)

0.299

0.584

Twins

17(3.10%)

9(5.00%)

1.33

0.249

24 h urine protein qualitative

50.25

 < 0.001***

  + 

189(35.10%)

34(18.80%)

  +  + 

206(38.10%)

46(25.60%)

  +  +  + 

139(25.70%)

95(52.80%)

  +  +  +  + 

6(1.10%)

5(2.80%)

Periodic antenatal examination

422(78.10%)

132(73.30%)

1.764

0.184

Edema

182(33.70%)

82(45.60%)

8.166

0.004**

Pain and chest distress

2(0.40%)

2(1.10%)

1.341

0.247

Expiratory dyspnea

1(0.20%)

1(0.60%)

0.669

0.414

Nausea and vomiting

1(0.20%)

3(1.70%)

5.363

0.021*

Dizziness and headache

25(4.60%)

20(11.10%)

9.679

0.002**

Blurred vision

18(3.30%)

13(7.20%)

4.955

0.026*

Respiratory disease

2(0.40%)

0(0.00%)

0.669

0.414

Cardiovascular disease

12(2.20%)

7(3.90%)

1.46

0.227

GDM

133(24.60%)

33(18.30%)

3.017

0.082

Immune system disease

3(0.60%)

1(0.60%)

0

1

Fundus disease

13(2.40%)

12(6.70%)

7.307

0.007**

Thyroid disease

58(10.70%)

16(8.90%)

0.502

0.479

ICP

34(6.30%)

22(12.20%)

6.609

0.01*